The US government has prioritised the development of next-generation vaccines targeted at anthrax that will provide improvements over the currently licensed vaccine, produced from filtered cultures of the attenuated pathogen. In this article, Dr Carrie Schneider and Dr Hubert C. Chen at Pfenex describe the potential of an mrPA-based anthrax vaccine to deliver an improved safety and immunogenicity profile relative to the currently licensed vaccine.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2018/12/An-efficacious-anthrax-vaccine.pdf” width=”100%” height=”900px” style=”border:0;”]